PunchBurn replaces injured Guéhi in England squad for Croatia, Spain games The Jerusalem PostEisenkot seeks haredi parties' support to oust Knesset Speaker Ohana on inauguration day InquirerPagadian City hosts 2026 MindaCon, more tech investments seen Complete SportsDarts’ Most Global Worlds: The Qualifiers From Kenya, India, Argentina And The Philippines 20 MinutenKnochen des heiligen Nikolaus gestohlen – und verbrannt ZDF heuteEntdecken Sie das ZDF-Nachrichtenstudio CBS NewsMississippi Senate race still a toss-up; Democrat holds slim lead Golem.deAnzeige: Robuste Taschenlampe von Shadowhawk für nur 17,96 Euro bei Amazon VanguardPower outages resolved, stable electricity in 3–5 years — Tegbe Seeking AlphaAN2 Therapeutics GAAP EPS of -$0.17 RTP DesportoFlávio Nazinho chamado à seleção portuguesa Il Fatto QuotidianoCarroponte cade in un forno elettrico in un’acciaieria turca durante una colata di acciaio fuso: “Almeno 6 morti” – Video

Seeking Alpha·United States·Monday, November 9, 2026 at 12:05 PM UTC

TG Therapeutics GAAP EPS of $0.35 misses by $0.01, revenue of $259.9M beats by $14.45M

Translate

Deepa Sarvaiya

TG Therapeutics press release (TGTX): Q3 GAAP EPS of $0.35 misses by $0.01.
Revenue of $259.9M (+60.7% Y/Y) beats by $14.45M.
Third-quarter 2026 total global revenue of approximately $260 million, including approximately $233 million in BRIUMVI U.S. net product revenue
Raises full-year 2026 total global revenue guidance to approximately $1 billion, from approximately $950 million vs $960.26M consensus
Raises full-year 2026 BRIUMVI U.S. net product revenue guidance to approximately $915–920 million, from $890–905 million
Shares +7% PM.

Recommended For You

Create Your Free Account to Keep Reading

Get the confidence to navigate an uncertain market with free breaking news and stock alerts.

View the original on Seeking Alpha →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.